Infectious diseases now最新文献

{"title":"From imprecise “immune debt” to nuanced “immune shortage”?","authors":"Luwen Zhang","doi":"10.1016/j.idnow.2024.104894","DOIUrl":"10.1016/j.idnow.2024.104894","url":null,"abstract":"","PeriodicalId":13539,"journal":{"name":"Infectious diseases now","volume":"54 5","pages":"Article 104894"},"PeriodicalIF":3.5,"publicationDate":"2024-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666991924000496/pdfft?md5=5abcdab9741932d83bdd80614f3b950d&pid=1-s2.0-S2666991924000496-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140318207","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Immune debt or immune shortage: The controversy continues – “Season 3 episode 1”","authors":"Robert Cohen, Corinne Levy","doi":"10.1016/j.idnow.2024.104897","DOIUrl":"10.1016/j.idnow.2024.104897","url":null,"abstract":"","PeriodicalId":13539,"journal":{"name":"Infectious diseases now","volume":"54 5","pages":"Article 104897"},"PeriodicalIF":3.5,"publicationDate":"2024-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666991924000526/pdfft?md5=00857bd86d2d975b9a30abbb383e9d29&pid=1-s2.0-S2666991924000526-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140326553","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bronchiolitis 2022–2023: One of the most unexpected outbreaks over this past decade, Nouvelle-Aquitaine, France","authors":"Gaëlle Gault ,&nbsp;Laure Meurice ,&nbsp;Anais Lamy ,&nbsp;Caroline Couturier ,&nbsp;Pascal Vilain ,&nbsp;Céline Etchetto ,&nbsp;Laurent Filleul","doi":"10.1016/j.idnow.2024.104896","DOIUrl":"10.1016/j.idnow.2024.104896","url":null,"abstract":"<div><h3>Background</h3><p>Since the Covid-19 pandemic, bronchiolitis outbreaks have been subject to disrupted seasonality, and a major impact on the healthcare system was observed in 2022–23.</p></div><div><h3>Objective</h3><p>The aim of this article is to describe the characteristics of the 2022–23 bronchiolitis epidemic in the Nouvelle-Aquitaine region, and its impact on the healthcare system.</p></div><div><h3>Method</h3><p>We described the indicators of dynamics, intensity, severity and impact provided by the bronchiolitis monitoring in place, and compared these with those from previous seasons.</p></div><div><h3>Results</h3><p>The intensity of the 2022–23 epidemic (emergency department visits: 23 %; SOS Médecins acts: 15 %), and its impact in terms of bronchiolitis-related hospitalizations (45 %) were higher than in previous seasons (p &lt; 0.05).</p></div><div><h3>Conclusion</h3><p>In addition to earliness, the 2022–23 bronchiolitis epidemic was significant as regards its exceptional scale and major impact on the hospital system, requiring adaptation of the preexisting healthcare offer in response to the anticipated demand.</p></div>","PeriodicalId":13539,"journal":{"name":"Infectious diseases now","volume":"54 4","pages":"Article 104896"},"PeriodicalIF":3.5,"publicationDate":"2024-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666991924000514/pdfft?md5=5f1c60496214225fc1d939205d7d5a5c&pid=1-s2.0-S2666991924000514-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140318205","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prevalence of antimicrobial use and healthcare-associated infections in the UAE: Results from the first nationwide point-prevalence survey","authors":"Najiba Abdulrazzaq,&nbsp;Ayman Chkhis","doi":"10.1016/j.idnow.2024.104891","DOIUrl":"10.1016/j.idnow.2024.104891","url":null,"abstract":"<div><h3>Objectives</h3><p>The WHO’s Global Antimicrobial Resistance Surveillance System (GLASS) 2017–2018 reported a significant increase in antimicrobial resistance among nosocomial pathogens. This was the first national point of prevalence survey in United Arab Emirates.</p></div><div><h3>Methods</h3><p>A one-day multicenter cross-sectional survey using a unified web-based platform was conducted in forty-four hospitals across the country from 3 to 23 November 2019 to estimate the prevalence of antimicrobial use and healthcare-associated infections among both governmental and private sectors.</p></div><div><h3>Results</h3><p>All in all, 3657 inpatients in the 44 participating hospitals were surveyed; 51.4 % were on at least one antibiotic at that time. Pneumonia was the most frequently reported hospital-acquired (47 %), followed by intra-abdominal sepsis (10.9 %), upper respiratory tract infections (10.6 %), and urinary tract infections (9.9 %). Ceftriaxone and piperacillin/Tazobactam were the most frequently used antibiotics (13.5 %, 9.6 %). Compliance with guidelines was reported in 70.3 % of prescriptions. Only 11.4 % of patients received a single dose of surgical prophylaxis.</p></div><div><h3>Conclusion</h3><p>Our results on antimicrobial use and hospital-acquired infection prevalence are comparable to other regional and international findings. Local guidelines are needed to reduce the excessive use of Watch and Reserve antibiotics, reduce prolonged antibiotic use after surgery, and decrease hospital-acquired infections.</p></div>","PeriodicalId":13539,"journal":{"name":"Infectious diseases now","volume":"54 4","pages":"Article 104891"},"PeriodicalIF":3.5,"publicationDate":"2024-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666991924000460/pdfft?md5=6b0cfca94b95eb83562cda3ac6887300&pid=1-s2.0-S2666991924000460-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140305513","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Environment, animals, and food as reservoirs of antibiotic-resistant bacteria for humans: One health or more?","authors":"Daniel Martak ,&nbsp;Charles P. Henriot ,&nbsp;Didier Hocquet","doi":"10.1016/j.idnow.2024.104895","DOIUrl":"10.1016/j.idnow.2024.104895","url":null,"abstract":"<div><p>Antimicrobial resistance (AMR) is a major public health challenge. For several years, AMR has been addressed through a One Health approach that links human health, animal health, and environmental quality. In this review, we discuss AMR in different reservoirs with a focus on the environment. Anthropogenic activities produce effluents (sewage, manure, and industrial wastes) that contaminate soils and aquatic environments with antibiotic-resistant bacteria (ARB), antibiotic-resistant genes (ARGs), and selective agents such as antibiotics, biocides, and heavy metals. Livestock treated with antibiotics can also contaminate food with ARB. In high-income countries (HICs), effective sanitation infrastructure and limited pharmaceutical industries result in more controlled discharges associated with human activities. Hence, studies using genome-based typing methods have revealed that, although rare inter-reservoir transmission events have been reported, human acquisition in HICs occurs primarily through person-to-person transmission. The situation is different in low- and middle-income countries (LMICs) where high population density, poorer sanitation and animal farming practices are more conducive to inter-reservoir transmissions. In addition, environmental bacteria can be a source of ARGs that, when transferred to pathogenic species under antibiotic selection pressure in environmental hotspots, produce new antibiotic-resistant strains that can potentially spread in the human community through human-to-human transmission.</p><p>The keys to reducing AMR in the environment are (<em>i</em>) better treatment of human waste by improving wastewater treatment plants (WWTPs) in HICs and improving sanitation infrastructure in LMICs, (<em>ii</em>) reducing the use of antibiotics by humans and animals, (<em>iii</em>) prioritizing the use of less environmentally harmful antibiotics, and (<em>iv</em>) better control of pharmaceutical industry waste.</p></div>","PeriodicalId":13539,"journal":{"name":"Infectious diseases now","volume":"54 4","pages":"Article 104895"},"PeriodicalIF":3.5,"publicationDate":"2024-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666991924000502/pdfft?md5=a2240314b0f7bfbbb572fcd3c679765f&pid=1-s2.0-S2666991924000502-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140318206","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hypervirulent Klebsiella pneumoniae-related bacteremia in intensive care unit: A retrospective cohort study","authors":"Marin Moutel ,&nbsp;Edwidge Peju ,&nbsp;Martin Belan ,&nbsp;Ariane Gavaud ,&nbsp;Jean-Paul Mira ,&nbsp;Caroline Charlier ,&nbsp;Etienne Canouï ,&nbsp;Nabil Gastli","doi":"10.1016/j.idnow.2024.104892","DOIUrl":"10.1016/j.idnow.2024.104892","url":null,"abstract":"<div><h3>Introduction</h3><p>Hypervirulent <em>Klebsiella pneumoniae</em> (hvKP) bloodstream infections (BSI) have rarely been reported in critically ill patients.</p></div><div><h3>Methods</h3><p>We conducted a retrospective study of KP-BSI between January 2016 and December 2020 in an adult medical intensive care unit (ICU) of our tertiary care hospital. Hypervirulent phenotype was defined by the detection of both <em>rmpA</em> and <em>iutA</em>.</p></div><div><h3>Results</h3><p>Seventy patients diagnosed with <em>K. pneumonia</em> BSI were included, of whom 9 (13 %) had hvKP infection. Pneumonia accounted for 56 % of hvKP-BSI and for 28 % of those with cKP. Fifty-six percent of patients with hvKP-BSI were homeless, versus 2 % of those with cKP-BSI (p &lt; 0.001). The 30-day mortality rate reached 44 % for hvKP-BSI and 34 % for cKP-BSI (p = 0.7) and did not appear related to the hypervirulent phenotype in multivariable analysis.</p></div><div><h3>Discussion</h3><p>We here evidenced a new clinical entity of hvKP-BSI associated with pulmonary infection in homeless patients, which exhibits high mortality.</p></div>","PeriodicalId":13539,"journal":{"name":"Infectious diseases now","volume":"54 5","pages":"Article 104892"},"PeriodicalIF":3.5,"publicationDate":"2024-03-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666991924000472/pdfft?md5=9cf799d0fb96473699775caf56c62378&pid=1-s2.0-S2666991924000472-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140193712","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Incidence of COVID-19 mRNA vaccine symptomatic breakthrough infections during Omicron circulation in adults with or without infection prior to vaccination","authors":"Christine Durier ,&nbsp;Laetitia Ninove ,&nbsp;Sylvie van der Werf ,&nbsp;Maeva Lefebvre ,&nbsp;Corinne Desaint ,&nbsp;Rebecca Bauer ,&nbsp;Mikael Attia ,&nbsp;Anne-Sophie Lecompte ,&nbsp;Marie Lachatre ,&nbsp;Zoha Maakaroun-Vermesse ,&nbsp;Jean-François Nicolas ,&nbsp;Renaud Verdon ,&nbsp;Jean-Jacques Kiladjian ,&nbsp;Paul Loubet ,&nbsp;Catherine Schmidt-Mutter ,&nbsp;Violaine Corbin ,&nbsp;Séverine Ansart ,&nbsp;Giovanna Melica ,&nbsp;Martine Resch ,&nbsp;Emmanuelle Netzer ,&nbsp;Odile Launay","doi":"10.1016/j.idnow.2024.104886","DOIUrl":"10.1016/j.idnow.2024.104886","url":null,"abstract":"<div><h3>Objectives</h3><p>COVID-19 vaccine breakthrough infections were frequently reported during circulation of the Omicron variant. The ANRS|MIE CoviCompareP study investigated these infections in adults vaccinated and boosted with BNT162b2 [Pfizer-BioNTech] and with/without SARS-CoV-2 infection before vaccination.</p></div><div><h3>Methods</h3><p>In the first half of 2021, healthy adults (aged 18–45, 65–74 and 75 or older) received either one dose of BNT162b2 (n = 120) if they had a documented history of SARS-CoV-2 infection at least five months previously, or two doses (n = 147) if they had no history confirmed by negative serological tests. A first booster dose was administered at least 6 months after the primary vaccination, and a second booster dose, if any, was reported in the database. Neutralizing antibodies (NAbs) against the European (D614G) strain and the Omicron BA.1 variant were assessed up to 28 days after the first booster dose. A case-control analysis was performed for the 252 participants who were followed up in 2022, during the Omicron waves.</p></div><div><h3>Results</h3><p>From January to October 2022, 78/252 (31%) had a documented symptomatic breakthrough infection after full vaccination: 21/117 (18%) in those who had been infected before vaccination vs. 57/135 (42%) in those who had not. In a multivariate logistic regression model, factors associated with a lower risk of breakthrough infection were older age, a higher number of booster doses, and higher levels of Omicron BA.1 NAb titers in adults with infection before vaccination, but not in those without prior infection.</p></div><div><h3>Conclusion</h3><p>Our results highlight the need to consider immune markers of protection in association with infection and vaccination history.</p></div>","PeriodicalId":13539,"journal":{"name":"Infectious diseases now","volume":"54 5","pages":"Article 104886"},"PeriodicalIF":3.5,"publicationDate":"2024-03-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666991924000411/pdfft?md5=aaacb841a5cac9a48c888a300822c7d4&pid=1-s2.0-S2666991924000411-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140143339","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"One-year follow-up of COVID-19 recoverees with impaired pulmonary function: A prospective cohort study","authors":"Nitzan Karny Epstein ,&nbsp;Dana Yelin ,&nbsp;Dorit Shitenberg ,&nbsp;Dafna Yahav ,&nbsp;Leonard Leibovici ,&nbsp;Vered Daitch ,&nbsp;Ili Margalit","doi":"10.1016/j.idnow.2024.104890","DOIUrl":"10.1016/j.idnow.2024.104890","url":null,"abstract":"<div><p>Decreased diffusion capacity for carbon monoxide (DLCO) is the most prevalent pulmonary testing abnormality among COVID-19 recoverees. We prospectively followed 51 individuals with impaired DLCO at an average of ∼3 months following COVID-19 and re-examined them at one year. At follow-up, mean DLCO increased from 68.0 % to 72.6 % (<em>p</em> = 0.002); while 33 % of the cohort experienced a clinically significant rise (&gt;10 points) in DLCO, only 29 % normalized their values. While DLCO change did not correlate with symptoms, lack of improvement was more prevalent among individuals with obesity. Regardless of COVID-19 severity, a substantial proportion continued to exhibit DLCO impairment at 1-year.</p></div>","PeriodicalId":13539,"journal":{"name":"Infectious diseases now","volume":"54 3","pages":"Article 104890"},"PeriodicalIF":3.5,"publicationDate":"2024-03-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666991924000459/pdfft?md5=e553a19d421b1dc81885a5e61fa68a29&pid=1-s2.0-S2666991924000459-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140158069","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Significantly reduced duration of antibiotic prescription for erysipelas subsequent to the 2019 French guidelines on skin and soft tissue infection: A before-after study","authors":"Justin Destoop ,&nbsp;Clélia Vanhaecke ,&nbsp;Firouzé Bani-Sadr ,&nbsp;Yannick Plenier ,&nbsp;Manuelle-Anne Viguier ,&nbsp;Maxime Hentzien","doi":"10.1016/j.idnow.2024.104887","DOIUrl":"10.1016/j.idnow.2024.104887","url":null,"abstract":"<div><h3>Background</h3><p>New skin and soft tissue infections (SSTI) guidelines were published in 2019 in France, changing the recommended duration for antibiotic treatment. The objective of the present study was to assess the impact of the publication of the 2019 French guidelines on SSTIs on the duration of antibiotic prescription for erysipelas.</p></div><div><h3>Methods</h3><p>In a before-after study (a year before and a year after April 1st, 2019), we included all adult patients diagnosed with erysipelas in Reims University Hospital medical wards and the emergency department. We retrospectively retrieved antibiotic prescription duration in the patients’ medical files.</p></div><div><h3>Results</h3><p>Among 50 patients in the “before” and 39 in the “after” group, the mean duration of antibiotic prescription was significantly shorter in the “after” group (9.4 ± 2.8 vs. 12.4 ± 3.8 days, p = 0.0001).</p></div><div><h3>Conclusions</h3><p>A 25% decrease in the duration of antibiotic prescription for erysipelas was observed following the implementation of these guidelines, providing useful information for an antibiotic stewardship policy.</p></div>","PeriodicalId":13539,"journal":{"name":"Infectious diseases now","volume":"54 3","pages":"Article 104887"},"PeriodicalIF":3.5,"publicationDate":"2024-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666991924000423/pdfft?md5=9005c33512532769335673b360d5b4f8&pid=1-s2.0-S2666991924000423-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140140186","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Secondary organizing pneumonia associated with protracted COVID: A case series","authors":"P-Y. Sansen ,&nbsp;E. Coche ,&nbsp;P. Hainaut ,&nbsp;A. Froidure ,&nbsp;A. Scohy ,&nbsp;B. Ghaye ,&nbsp;L. Belkhir ,&nbsp;J. De Greef","doi":"10.1016/j.idnow.2024.104888","DOIUrl":"10.1016/j.idnow.2024.104888","url":null,"abstract":"<div><h3>Objectives</h3><p>Immunocompromised B-cell-depleted patients are at risk of developing protracted COVID-19, a clinical syndrome characterized by prolonged viral shedding and respiratory symptoms that can lead to hypoxemic pneumonia. Our aim is to describe this unusual condition and its treatment.</p></div><div><h3>Patients and methods</h3><p>This monocentric retrospective study reports six cases of severe organizing pneumonia that developed during the clinical course of protracted COVID-19.</p></div><div><h3>Results</h3><p>All patients developed organizing pneumonia (OP) in the setting of protracted COVID. Clinical improvement was obtained after several treatment lines including specific antiviral agents and occurred simultaneously with control of the viral load.</p></div><div><h3>Conclusion</h3><p>As it was the most frequent presentation of protracted COVID-19 in our survey, we believe that this specific form of organizing pneumonia warrants increased awareness. Furthermore, specific antiviral therapy seems to control this condition.</p></div>","PeriodicalId":13539,"journal":{"name":"Infectious diseases now","volume":"54 3","pages":"Article 104888"},"PeriodicalIF":3.5,"publicationDate":"2024-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666991924000435/pdfft?md5=603874ecaebf02e9c613d6180cec72f0&pid=1-s2.0-S2666991924000435-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140143340","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}